TRex Bio, Inc.’s (NASDAQ:TRXB) Quiet Period Will End Tomorrow

TRex Bio’s (NASDAQ:TRXB – Get Free Report) quiet period is set to expire on Wednesday, November 18th. TRex Bio had issued 8,333,334 shares in its public offering on October 9th. The total size of the offering was $116,666,676 based on an initial share price of $14.00. During the company’s quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on TRXB shares. Wedbush initiated coverage on TRex Bio in a research report on Monday, November 2nd. They issued an “outperform” rating and a $30.00 price target for the company. JPMorgan Chase & Co. started coverage on TRex Bio in a research report on Tuesday, November 3rd. They set an “overweight” rating and a $20.00 price objective on the stock. Cantor Fitzgerald assumed coverage on TRex Bio in a research report on Tuesday, November 3rd. They set an “overweight” rating on the stock. Zacks Research began coverage on TRex Bio in a research note on Tuesday, November 3rd. They set a “hold” rating on the stock. Finally, Evercore initiated coverage on TRex Bio in a report on Tuesday, November 3rd. They issued a “strong-buy” rating for the company. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $29.67.

View Our Latest Research Report on TRex Bio

TRex Bio Trading Down 21.2%

TRex Bio stock opened at $10.77 on Tuesday. TRex Bio has a 12-month low of $10.76 and a 12-month high of $16.56.

TRex Bio (NASDAQ:TRXB – Get Free Report) last posted its earnings results on Friday, November 13th. The company reported ($10.06) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($9.37). On average, equities analysts forecast that TRex Bio will post -4.28 EPS for the current year.

Insider Activity at TRex Bio

In other news, major shareholder Alexandria Venture Investments purchased 178,571 shares of TRex Bio stock in a transaction dated Tuesday, October 13th. The shares were purchased at an average price of $14.00 per share, with a total value of $2,499,994.00. Following the transaction, the insider owned 1,346,501 shares in the company, valued at $18,851,014. This represents a 15.29% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

About TRex Bio

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.

See Also

Receive News & Ratings for TRex Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRex Bio and related companies with MarketBeat.com's FREE daily email newsletter.